Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry

Blood (2023) 142 (Supplement 1): 6471.

https://doi.org/10.1182/blood-2023-177787

Published: 2023

Journal Articles

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Blood (2022) 140 (Supplement 1): 8996–8998.

https://doi.org/10.1182/blood-2022-159125

Published: 2022

Journal Articles

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Charles Herbaux, Stéphanie Poulain, Damien Roos-Weil, Jacques-Olivier Bay, Yann Guillermin, Francois Lemonnier, Kamel Laribi, Sorin Visanica, Jerome Moreaux, Hugo Gonzalez, Maxime Jullien, Abderrazak El Yamani, Houria Debarri, Sophie Godet, Franck Morschhauser, Olivier Tournilhac, Matthew S. Davids, Loic Ysebaert

Blood (2021) 138 (Supplement 1): 1201.

https://doi.org/10.1182/blood-2021-149228

Published: 2021

Journal Articles

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Blood (2014) 124 (21): 2327.

https://doi.org/10.1182/blood.V124.21.2327.2327

Published: 2014

Journal Articles

Efficacy and Safety Profile of Long Term Exposure to Lenalidomide in Relapsed Multiple Myeloma.

Guillemette Fouquet, MD, Stéphanie Tardy, MD, Helene Demarquette, MD, Sarah Bonnet, MD, Julie Gay, MD, Houria Debarri, MD, Charles Herbaux, MD, Jessica Michel, MD, Aurore Perrot, MD, Caroline Serrier, MD, Suzanne K. Robinson, PhD, Darko Miljkovic, Pascale Morel, Catherine Boccacio, Herve AvetLoiseau, MD, Thierry Facon, MD, Cyrille Hulin, MD, Xavier Leleu, MD, PhD

Blood (2012) 120 (21): 2964.

https://doi.org/10.1182/blood.V120.21.2964.2964

Published: 2012

Journal Articles

IgA Hevylite® Test As a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA Myeloma

Eileen Mary Boyle, MD, Philip Young, Helene Demarquette, MD, Julie Gay, MD, Houria Debarri, MD, Sarah Bonnet, MD, Charles Herbaux, MD, Remy Dulery, MD, Salomon Manier, MD, Jean-Luc Faucompre, Frederic Combat, MD, Annie Pietrantuono, MD, Brigitte Onraed, Bernadette Hennache, Thierry Facon, MD, Stephen J Harding, MD, PhD, Xavier Leleu, MD, PhD

Blood (2012) 120 (21): 3970.

https://doi.org/10.1182/blood.V120.21.3970.3970

Published: 2012

Journal Articles

Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia

Salomon Manier, MD, Julie Lejeune, Lucile Musset, MD, Eileen Boyle, MD, Remy Dulery, MD, Houria Debarri, MD, Jean-Luc Faucompret, Jordan Gauthier, MD, Claire Bories, MD, Guillemette Fouquet, MD, Charles Herbaux, MD, Sabine Tricot, MD, Annie Pietrantuono, MD, Frederic Combat, MD, Stephanie Poulain, MD, Stephen Harding, MD, PhD, Véronique Leblond, MD, PhD, Xavier Leleu, MD, PhD

Blood (2011) 118 (21): 2667.

https://doi.org/10.1182/blood.V118.21.2667.2667

Published: 2011

Journal Articles

The EOS ® System for the Detection of Bone Lesions in Patients with Multiple Myeloma,

Bastien Dutouquet, MD, Xavier Leleu, MD, PhD, Antoine Moraux, MD, Eileen Boyle, MD, Jordan Gauthier, MD, Houria Debarri, MD, Salomon Manier, MD, Marie Pierre Noel, MD, Thierry Facon, MD, Marie Helene Vieillard, MD, PhD, Anne Cotten, MD, Nathalie Boutry, MD, PhD

Blood (2011) 118 (21): 3921.

https://doi.org/10.1182/blood.V118.21.3921.3921

Published: 2011

Journal Articles

Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).

Sophie Dupire, Houria Debarri, Laurent Pascal, Valerie Coiteux, Benedicte Hivert, Christophe Willekens, Julien Rossignol, Ibrahim Yakoub-Agha, MD, PhD, Brigitte Onraed, Jean-Luc Faucompré, Bernadette Hennache, Charles Dumontet, Thierry Facon, Xavier Leleu

Blood (2009) 114 (22): 2493.

https://doi.org/10.1182/blood.V114.22.2493.2493

Published: 2009

Journal Articles

Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs?

Driss Chaoui, Xavier Leleu, Murielle Roussel, Bruno Royer, Marie-therese Rubio, Sophie Ducastelle, MD, Fatiha Merabet, Laurent Garderet, Brigitte Kolb, Houria Debarri, Yazid Arkam, Jean-Luc Harousseau, Philippe Moreau, MD

Blood (2009) 114 (22): 3869.

https://doi.org/10.1182/blood.V114.22.3869.3869

Published: 2009

Journal Articles

Effectiveness of Second Line Treatment in AL Amyloidosis Patients Refractory to M-Dex.

Julie Abraham, Houria Debarri, Amelie Penot, Estelle Desport, Claire Aguilar, Fatima Yagoubi, Xavier Leleu, Alain Goldstein, Dominique Bordessoule, Brigitte Kolb, Franck Bridoux, Jean-Paul Fermand, Veronique Leblond, Arnaud Jaccard

Blood (2009) 114 (22): 4930.

https://doi.org/10.1182/blood.V114.22.4930.4930

Published: 2009

Journal Articles

Peripheral Blood Stem Cell (PBSC) Harvest Is More Expensive Following Bortezomib-Based Therapy in Multiple Myeloma (MM), Related to Increase Number of Days of Collect.

Matthieu Barthelemy, Florence Boulanger, MD, Houria Debarri, Laurent Pascal, Pierre Samarcq, MD, Colette Cossement, MD, Jean-Pierre Jouet, MD, Thierry Facon, MD, Ibrahim Yakoub-Agha, MD, PhD, Xavier Leleu

Blood (2009) 114 (22): 1373.

https://doi.org/10.1182/blood.V114.22.1373.1373

Published: 2009

NARROW

Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Efficacy and Safety Profile of Long Term Exposure to Lenalidomide in Relapsed Multiple Myeloma.

IgA Hevylite® Test As a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA Myeloma

Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia

The EOS ® System for the Detection of Bone Lesions in Patients with Multiple Myeloma,

Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).

Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs?

Effectiveness of Second Line Treatment in AL Amyloidosis Patients Refractory to M-Dex.

Peripheral Blood Stem Cell (PBSC) Harvest Is More Expensive Following Bortezomib-Based Therapy in Multiple Myeloma (MM), Related to Increase Number of Days of Collect.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only